surpass-cvot tirzepatide 🫀 EASD 2025: (SURPASS-CVOT) Dulaglutide head-to-head showdown: ✓ Noninferior for MACE ✓ 16% ↓ all-cause mortality ✓ Superior in A1C & weight loss Tirzepatide confirms its broad cardiometabolic edge. #EASD2025 # Tirzepatide #GLP1 SURPASS-CVOT trial: For patients with

Do not attempt to start at a "comparable" high dose

Resistance training is not optional when you are on GLP-1 medications

Tirzepatide's half-life is approximately five days, meaning most of the compound leaves your body within 23 weeks

Tirzepatide can be a well-tolerated and extremely effective weight loss treatment option for overweight and obese adults

Brello stands out by integrating personalized coaching, progress tracking, and frequent clinician follow-ups to help patients create lasting lifestyle changes, not just short-term weight loss

Benefits Weekly self-injectable pen used for weight loss Contains tirzepatide Helps reduce appetite and prevent cravings Directions for Use Inject your prescribed dose via subcutaneous injection once per week as directed